Antoine Adenis

Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study

Bohuslav Melichar, Antoine Adenis, A. Craig Lockhart et al. · The Lancet Oncology · 2015 · 248 citations

Investigational Aurora, Medicine, Pharmacology +7

Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era

Philippe A. Cassier, Elena Fumagalli, Piotr Rutkowski et al. · Clinical Cancer Research · 2012 · 232 citations · Full text

Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial

Aurore Blesius, Philippe A. Cassier, François Bertucci et al. · BMC Cancer · 2011 · 126 citations · Full text

Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST)

Axel Le Cesne, Jean‐Yves Blay, Binh Bui et al. · European Journal of Cancer · 2010 · 123 citations

Oral Masitinib Mesilate, Surgical Oncology, Gastrointestinal Oncology +10

Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial

Olivier Mir, Claire Cropet, Maud Toulmonde et al. · The Lancet Oncology · 2016 · 120 citations

Open-label Phase 2, Gastrointestinal Oncology, Medicine +7